This study is looking at how a medication called Dapagliflozin might affect atrial fibrillation (AF), a type of irregular heartbeat, in people who also have diabetes. Researchers want to see if Dapagliflozin can reduce the amount of time you spend in AF. You would take either Dapagliflozin 10mg or a placebo (an inactive pill) once a day. This study is for adults aged 18 to 85 who have been diagnosed with diabetes and paroxysmal AF (AF that stops on its own or with help within seven days). You cannot join if you have Type 1 diabetes, very low blood pressure, severe kidney problems, or are taking certain other medications. The study aims to enroll 28 participants.

Study design

This is an interventional study where participants will be randomly assigned to receive either Dapagliflozin or a placebo. The study is blinded, meaning neither you nor your doctor will know which treatment you are receiving.

What's involved

You would take one blinded tablet daily. Your heart rhythm will be monitored continuously for two weeks at the beginning and again at three months.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring the effect of Dapagliflozin is at 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.